Company Overview

Revvity, Inc. is a U.S.-based life sciences and diagnostics company that develops technologies, instruments, software, assays, and services used in biomedical research, clinical diagnostics, reproductive health, and applied testing markets. The company operates primarily within the healthcare, biotechnology, pharmaceutical, and laboratory services industries. Revvity was formerly known as PerkinElmer, Inc. and adopted the Revvity name in 2023 following a strategic repositioning toward life sciences and diagnostics after divesting several non-core industrial and applied businesses.

The company’s primary revenue drivers include laboratory instruments, diagnostics platforms, reagent kits, informatics software, genomic and cellular analysis technologies, and contract laboratory services. Revvity serves pharmaceutical and biotechnology companies, hospitals, clinical laboratories, academic institutions, and government agencies. Its positioning is supported by a broad installed base of analytical instruments, recurring consumables revenue, and integration across diagnostics, imaging, genomics, and informatics workflows. Public filings and investor materials indicate the company has increasingly focused on higher-growth and higher-margin healthcare-related markets, particularly precision medicine, reproductive health, and translational research.

Business Operations

Revvity organizes its operations primarily through two major segments: Life Sciences and Diagnostics. The Life Sciences segment provides imaging systems, detection technologies, automation platforms, software, and reagents used in drug discovery, cellular analysis, and translational research. The Diagnostics segment includes reproductive health screening, immunodiagnostics, newborn screening, infectious disease testing, and laboratory services. Revenue is generated through a combination of instrument sales, recurring consumables, software licensing, maintenance contracts, and laboratory testing services.

The company maintains operations across North America, Europe, Asia-Pacific, Latin America, and the Middle East. Revvity controls a portfolio of proprietary technologies in genomics, immunoassays, chemiluminescence, imaging, flow-based analysis, and laboratory automation. Key subsidiaries and acquired businesses include Oxford Immunotec, BioLegend, and several historical PerkinElmer diagnostics and genomics assets. Revvity also maintains collaborations with pharmaceutical companies, clinical laboratories, and research institutions to support biomarker discovery, companion diagnostics, and precision medicine initiatives.

Strategic Position & Investments

Revvity’s strategy centers on expanding its presence in precision health, advanced diagnostics, and biologics research tools while increasing recurring revenue from consumables and services. Company disclosures and investor presentations emphasize investments in genomics, cell and gene therapy workflows, AI-enabled informatics, and translational research solutions. The rebranding from PerkinElmer to Revvity accompanied a portfolio transformation designed to concentrate resources on life sciences and diagnostics rather than industrial analytical businesses.

Major acquisitions have included BioLegend, a provider of antibodies and reagents for immunology and cell biology research, and Oxford Immunotec, which strengthened Revvity’s immunodiagnostics capabilities. The company has also invested in laboratory automation, digital workflow platforms, and next-generation screening technologies. Revvity continues to position itself within emerging healthcare areas such as multi-omics research, reproductive health diagnostics, oncology testing support, and advanced biologics development. Data regarding future acquisition priorities beyond publicly disclosed strategic themes remains inconclusive based on available public sources.

Geographic Footprint

Revvity is headquartered in Waltham, Massachusetts, United States, and maintains operations, manufacturing facilities, laboratories, and commercial offices across multiple global regions. The company has a significant presence in North America, Europe, and Asia-Pacific, with customers spanning pharmaceutical research centers, hospital systems, public health organizations, and academic laboratories worldwide.

Internationally, Revvity derives a substantial portion of revenue from markets outside the United States, particularly in Europe, China, Japan, and other developed healthcare and research markets. Its global footprint includes direct sales operations, distributor networks, laboratory service facilities, and manufacturing capabilities supporting diagnostics and life sciences products. Public disclosures indicate the company’s international strategy focuses on expanding diagnostic adoption, research infrastructure partnerships, and precision medicine applications across both mature and emerging healthcare markets.

Leadership & Governance

Revvity’s leadership structure reflects its focus on scientific innovation, operational efficiency, and healthcare market expansion. The company evolved from the long-established PerkinElmer, Inc., which was founded in 1937 and historically focused on analytical instruments and scientific technologies. Under current leadership, Revvity has emphasized portfolio transformation toward life sciences and diagnostics, supported by acquisitions and divestitures intended to sharpen strategic focus.

Key executives include:

• Prahlad Singh – President and Chief Executive Officer
• Jamey Mock – Senior Vice President and Chief Financial Officer
• Dirk Bontridder – Senior Vice President and President, Diagnostics
• Kevin Quick – Senior Vice President and President, Life Sciences
• Delphine Bernard – Senior Vice President, Chief Human Resources Officer
• Michael Harrington – Senior Vice President, General Counsel and Secretary

Leadership communications in annual reports and investor materials consistently emphasize innovation-driven growth, operational discipline, recurring revenue expansion, and integrated workflows supporting precision health and translational science. Governance practices are overseen by the company’s board of directors and disclosed through SEC filings, including annual proxy statements and Form 10-K reports.